Taken together, adenosine released in an inflammatory milieu or generated by the CD39/CD73 axis will impact the immune landscape of lung tumors presumably by limiting T cell immunity and promoting immunosuppressive and tumor-promoting lymphoid and myeloid immune cell phenotypes (Figure 1). This evidence concerns the gene ENTPD1 and neoplasm.